Syncom Formulations (India) Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 on April 7, 2026. Company Secretary and Compliance Officer Vaishali Agrawal digitally signed and submitted the document to both BSE and NSE.

Dematerialization Process Confirmation

The compliance certificate confirms that all securities received from depository participants for dematerialization during Q4FY26 were properly processed. Ankit Consultancy Pvt Ltd, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate.

CS Saurabh Maheshwari, Compliance Officer at Ankit Consultancy Pvt Ltd, certified that:

• All securities received for dematerialization were confirmed to depositories
• Security certificates have been listed on stock exchanges where earlier securities are listed
• Physical certificates were mutilated and cancelled after verification
• Depository names were substituted in the register of members within 15 days

Regulatory Framework

The filing addresses requirements under the current SEBI (Depositories and Participants) Regulation 2018, which replaced the earlier 1996 regulations. This quarterly compliance ensures transparency in the dematerialization process and maintains investor confidence in electronic securities handling.

Distribution and Documentation

Copies of the compliance certificate were sent to key market infrastructure institutions including National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), ensuring comprehensive regulatory compliance across all relevant authorities.

Syncom formulations (India) Limited has filed its annual disclosure under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The WHO-GMP and ISO 9001:2015 certified pharmaceutical company submitted the mandatory yearly disclosure to stock exchanges and its Audit Committee on April 6, 2026.

Regulatory Compliance Filing

The disclosure was filed pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary and Compliance Officer Vaishali Agrawal submitted the filing to both BSE Limited and National Stock Exchange of India Limited on behalf of the company.

Promoter Declarations

Both promoters of Syncom Formulations have provided individual declarations confirming compliance with SEBI regulations. The declarations were signed on April 3, 2026, from their respective locations.

Kedarmal Shankarlal Bankda Declaration

Kedarmal Shankarlal Bankda, Promoter and Whole-time Director (DIN: 00023050), declared that he and his persons acting in concert have not made any new encumbrances on company securities during FY26. His PAC group includes:

• Smt. Vimla Bankda (Person Acting in Concert)
• Shri Ankit Bankda (Person Acting in Concert)
• Kedarmal Shankarlal Bankda (HUF) (Person Acting in Concert)

Vijay Shankarlal Bankda Declaration

Vijay Shankarlal Bankda, Promoter and Managing Director (DIN: 00023027), submitted a similar declaration covering his extended PAC network of nine entities:

Corporate Information

Syncom Formulations operates from multiple locations with its registered office in Mumbai, corporate office in Indore, and manufacturing facility in Pithampur, Madhya Pradesh. The company maintains its commitment to regulatory compliance through timely submission of required disclosures to market regulators and stakeholders.